X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs AUROBINDO PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB AUROBINDO PHARMA DR. REDDYS LAB/
AUROBINDO PHARMA
 
P/E (TTM) x 27.9 17.8 156.5% View Chart
P/BV x 2.9 5.8 49.6% View Chart
Dividend Yield % 1.0 0.4 275.3%  

Financials

 DR. REDDYS LAB   AUROBINDO PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-16
AUROBINDO PHARMA
Mar-16
DR. REDDYS LAB/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs4,3831,541 284.5%   
Low Rs2,750582 472.5%   
Sales per share (Unadj.) Rs920.1237.5 387.5%  
Earnings per share (Unadj.) Rs126.133.9 372.3%  
Cash flow per share (Unadj.) Rs183.040.6 450.9%  
Dividends per share (Unadj.) Rs20.002.50 800.0%  
Dividend yield (eoy) %0.60.2 238.1%  
Book value per share (Unadj.) Rs685.8120.6 568.7%  
Shares outstanding (eoy) m170.61585.17 29.2%   
Bonus/Rights/Conversions ESOPPREF-  
Price / Sales ratio x3.94.5 86.7%   
Avg P/E ratio x28.331.3 90.3%  
P/CF ratio (eoy) x19.526.2 74.5%  
Price / Book Value ratio x5.28.8 59.1%  
Dividend payout %15.97.4 214.9%   
Avg Mkt Cap Rs m608,481621,041 98.0%   
No. of employees `00021.713.3 163.1%   
Total wages/salary Rs m31,87415,508 205.5%   
Avg. sales/employee Rs Th7,244.410,457.6 69.3%   
Avg. wages/employee Rs Th1,470.91,167.1 126.0%   
Avg. net profit/employee Rs Th992.81,491.6 66.6%   
INCOME DATA
Net Sales Rs m156,978138,961 113.0%  
Other income Rs m2,6931,663 162.0%   
Total revenues Rs m159,671140,624 113.5%   
Gross profit Rs m34,58732,056 107.9%  
Depreciation Rs m9,7053,926 247.2%   
Interest Rs m8242,568 32.1%   
Profit before tax Rs m26,75127,225 98.3%   
Minority Interest Rs m039 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,2377,444 70.4%   
Profit after tax Rs m21,51419,820 108.5%  
Gross profit margin %22.023.1 95.5%  
Effective tax rate %19.627.3 71.6%   
Net profit margin %13.714.3 96.1%  
BALANCE SHEET DATA
Current assets Rs m118,201100,015 118.2%   
Current liabilities Rs m68,36874,759 91.5%   
Net working cap to sales %31.718.2 174.7%  
Current ratio x1.71.3 129.2%  
Inventory Days Days60107 55.9%  
Debtors Days Days97110 88.4%  
Net fixed assets Rs m72,26552,350 138.0%   
Share capital Rs m853585 145.8%   
"Free" reserves Rs m111,54867,707 164.8%   
Net worth Rs m117,00970,567 165.8%   
Long term debt Rs m10,6908,472 126.2%   
Total assets Rs m200,104156,994 127.5%  
Interest coverage x33.511.6 288.4%   
Debt to equity ratio x0.10.1 76.1%  
Sales to assets ratio x0.80.9 88.6%   
Return on assets %11.214.3 78.3%  
Return on equity %18.428.1 65.5%  
Return on capital %21.637.7 57.2%  
Exports to sales %46.351.0 90.6%   
Imports to sales %9.018.8 47.5%   
Exports (fob) Rs m72,61870,927 102.4%   
Imports (cif) Rs m14,05026,193 53.6%   
Fx inflow Rs m75,40571,015 106.2%   
Fx outflow Rs m27,11528,799 94.2%   
Net fx Rs m48,29042,216 114.4%   
CASH FLOW
From Operations Rs m40,47617,596 230.0%  
From Investments Rs m-19,421-13,801 140.7%  
From Financial Activity Rs m-17,009-198 8,577.4%  
Net Cashflow Rs m4,0463,597 112.5%  

Share Holding

Indian Promoters % 25.5 54.1 47.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 8.0 67.9%  
FIIs % 35.3 27.7 127.4%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.2 150.0%  
Shareholders   75,885 69,601 109.0%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 23, 2017 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS